On June 2, 2026, Shanghai Shuyin Xinke Intelligent Technology Co., Ltd. proudly declared the successful closure of its Pre-A round financing. This pivotal funding round was spearheaded by Jia Bi You, a prominent entity listed on the Sci-Tech Innovation Board, and saw the active involvement of CSC Fund Management Capital, Lingang Digital Science and Technology Fund, Minjin Investment, and Kangrong Pharmaceutical. The capital infusion will be strategically allocated to expedite the progression of clinical pipelines, refine AI and high-throughput platforms, and delve into the siRNA consumer-grade raw material market. This move is set to propel Shuyin Zhike from the "platform capability validation phase" into a dynamic commercialization phase, fueled by the synergy of the "pharmaceuticals + consumer" sectors.

Headquartered in Shanghai and boasting a research and development hub in Beijing, Shuyin Zhike's core team is a constellation of talent from esteemed institutions including Harvard University, Carnegie Mellon University, Tsinghua University, Shanghai Jiao Tong University, and the Chinese Academy of Sciences. Notably, over half of its R&D staff possess doctoral degrees, underscoring the company's commitment to academic excellence and innovation.

Shuyin Zhike has been at the forefront of innovation, pioneering a closed-loop R&D model that seamlessly integrates AI prediction with high-throughput experimental validation. This groundbreaking approach has slashed the RNA drug development timeline from the conventional 3-5 years to a mere 6-9 months, marking a significant leap in efficiency and productivity. Moreover, the company has independently crafted a multi-tissue RNA delivery system, effectively addressing two critical challenges: ensuring the stability of RNA molecules and achieving targeted delivery with precision.